Magnus Halldin joined Astra in 1985, where he up to 2013 held various line and project management positions in the company, and contributed to bringing Ropivacaine and EMLA to the market. Magnus also had a scientific DMPK advisory role on numerous global scientific committees and knowledge groups, and in-licensing and due diligence opportunities within both Discovery and Development.
His research interest in drug metabolism